Advanced search
Publication Cover
Leukemia & Lymphoma Volume 9, 1993 - Issue 3
Submit an article Journal homepage
16
Views
7
CrossRef citations to date
0
Altmetric
Original Article

A Randomised Trial of Cyclophosphamide With and Without Low Dose Alpha-Interferon in the Treatment of Newly Diagnosed Myeloma

R. Aitchison Department of Haematology, Royal London Hospital, London, England
,
A. Williams Department of Haematology, Guys Hospital, London, England
,
S. Schey Department of Haematology, Guys Hospital, London, England
&
A. C. Newland Department of Haematology, Royal London Hospital, London, England
Pages 243-246 | Received 27 Jun 1991, Published online: 01 Jul 2009

References

  • Case D. C., Lee B. J., Clarkson B. D. Improved survival times in multiple myeloma treated with melphalan, prednisolone, cyclophosphamide, vincristine, BCNU: M2 protocol. Am. J. Med. 1977; 63: 897–903
  • Sporn J. R., McIntyre O. R. Chemotherapy of previously untreated multiple myeloma patients: an analysis of recent treatment results. Semin. Oncol. 1986; 13: 318–25
  • Selby P. J., McElwain T., Nandi A. C., et al. Multiple Myeloma treated with high dose intravenous melphalan. B. J. Haematol. 1987; 66: 55–62
  • Samson D., Newland A. C., Kearney J., et al. Infusion of vincristine and doxorubicin with oral dex-amethasone as first line therapy for multiple myeloma. Lancet 1989; ii: 882–85
  • Gore M. E., Viner C., Meldrum M., et al. Intensive treatment of multiple myeloma and criteria for complete remission. Lancet 1989; ii: 879–81
  • Barlogie B., Hall R., Zander A., Dickie K., Alexanian R. High dose Melphalan with Autologous transplantation for multiple myeloma. Blood 1986; 67: 1298–1301
  • Gahrton G., Tura S., Belanger C., et al. Allogeneic bone marrow transplantation in patients with multiple myeloma. Eur. J. Haematol. 1989; 43(Suppl 51)182–5
  • Kyle R. A. Multiple Myeloma a review of 869 cases. Mayo Clinic Proceedings 1975; 50: 29–40
  • Costanzi J. J., Pollard R. B. The use of interferon in the treatment of multiple myeloma. The Interferon System-a current review to 1987, Dianzan I. Baron, P. Stanton, 1987; 497–505
  • Quesada J. R., Alexanian R., Hawkins M., Barlogie B., et al. Treatment of multiple myeloma with recombinant alpha interferon. Blood 1986; 67: 275–78
  • Mandelli F., Avvisati S., Amadori S., et al. Maintenance treatment with recombinant interferon alfa-2B in patients with multiple myeloma responding to conventional induction chemotherapy. New England Journal of Medicine 1990; 322(20)1430–4
  • Medical Research Council Working Party on Leukaemia in Adults. Myelomatosis, comparison of melphalan and cyclophosphamide therapy. B.M.J. 1971; 1: 640–41
  • Korst D. R., Clifford G. O., Fowler W. M., Louis J., Will J., Wilson H. E. Multiple myeloma II, analysis of cyclophosphamide therapy in 165 patients. JAMA 1964; 189: 758–62
  • Mellstedt H., Osterborg A., Bjorkholm M., Bjoreman M., Brennning G. Treatment of multiple myeloma with interferon alpha: the Scandinavian Experience. British Journal of Haematology 1991; 79(Suppl 1)21–5
  • Monturoro A., De Rosa L., De Blasio A., Pacilli L., Petti N., De Laurenzi A. AIfa-2a-interferon/melphalan/-prednisone versus melphalan/prednisone in previously untreated patients with multiple myeloma. British Journal of Haematology 1990; 76: 365–68
  • MacLennan I. A. C., Chapman C., Dunn J., Kelly K. Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis. Lancet 1992; 339: 200–5
  • Ludwig H., Cohen A. M., Huber H., Nachbaur D., et al. Interferon Alfa-2b with VMCP compared to VMCP alone for induction and Interferon Alfa-2b compared to controls for remission maintenance in multiple myeloma: interim results. Eur. J. Cancer 1991; 27(Suppl. 4)S40–45
  • Case D. C., Sonneborn H. L., Paul S. D., et al. Phase II study of rDNA alpha-2 interferon (Intron A) in multiple myeloma utilizing an escalating induction phase. Cancer Treat. Rep. 1986; 70: 1251

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.